TY - JOUR
T1 - Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non–Small-Cell Lung Cancer
AU - Naidoo, Jarushka
AU - Nishino, Mizuki
AU - Patel, Sandip Pravin
AU - Shankar, Bairavi
AU - Rekhtman, Natasha
AU - Illei, Peter
AU - Camus, Phillipe
N1 - Funding Information:
J.N. has received grants from AstraZeneca and Merck during the conduct of the study, and has served as a consultant for/received honoraria from AstraZeneca, Roche/Genentech, and Bristol-Myers Squibb outside the submitted work. M.N. has received personal fees (consultancy) from Daiichi Sankyo and personal fees (honoraria) from Bayer and Roche, all outside the submitted work. M.N.’s institution has received research funding from the Merck Investigator Studies Program , Canon Medical Systems , AstraZeneca , and NIH , all outside the submitted work. S.P.P. has received scientific advisory income from AstraZeneca, Bristol-Myers Squibb, Illumina, Nektar, and Tempus. S.P.P.’s institution has received research funding from Bristol-Myers Squibb , Eli Lilly , Fate , Incyte , AstraZeneca /MedImmune, Merck , Pfizer , Roche /Genentech, Xcovery , Fate Therapeutics , Genocea , and Iovance . P.I. has received nonfinancial support (document preparation) from AstraZeneca during the conduct of the study, and has received personal fees from AstraZeneca and grants from Bristol-Myers Squibb outside the submitted work. The other authors have stated that they have no conflict of interest.
Funding Information:
J.N. has received grants from AstraZeneca and Merck during the conduct of the study, and has served as a consultant for/received honoraria from AstraZeneca, Roche/Genentech, and Bristol-Myers Squibb outside the submitted work. M.N. has received personal fees (consultancy) from Daiichi Sankyo and personal fees (honoraria) from Bayer and Roche, all outside the submitted work. M.N.?s institution has received research funding from the Merck Investigator Studies Program, Canon Medical Systems, AstraZeneca, and NIH, all outside the submitted work. S.P.P. has received scientific advisory income from AstraZeneca, Bristol-Myers Squibb, Illumina, Nektar, and Tempus. S.P.P.?s institution has received research funding from Bristol-Myers Squibb, Eli Lilly, Fate, Incyte, AstraZeneca/MedImmune, Merck, Pfizer, Roche/Genentech, Xcovery, Fate Therapeutics, Genocea, and Iovance. P.I. has received nonfinancial support (document preparation) from AstraZeneca during the conduct of the study, and has received personal fees from AstraZeneca and grants from Bristol-Myers Squibb outside the submitted work. The other authors have stated that they have no conflict of interest.Medical writing support, which was in accordance with Good Publication Practice (GPP3) guidelines, was provided by Aaron Korpal, PhD, and James King, BSc, of Cirrus Communications (Manchester, UK), an Ashfield company, and was funded by AstraZeneca.
Funding Information:
Medical writing support, which was in accordance with Good Publication Practice (GPP3) guidelines, was provided by Aaron Korpal, PhD, and James King, BSc, of Cirrus Communications (Manchester, UK), an Ashfield company, and was funded by AstraZeneca .
Publisher Copyright:
© 2020 The Author(s)
PY - 2020/9
Y1 - 2020/9
N2 - Approximately one third of patients with non–small-cell lung cancer (NSCLC) present with stage III or locally advanced NSCLC. These patients have historically been managed with chemoradiotherapy. However, outcomes for these patients remain poor, with a 5-year survival rate between 15% and 32%. Immune checkpoint inhibitors have revolutionized the treatment of patients with NSCLC. One such agent, durvalumab, a selective high-affinity human immunoglobulin G1 monoclonal antibody that blocks programmed cell death ligand 1 binding to programmed cell death protein 1 and cluster of differentiation 80, was recently approved in the consolidation setting after completion of definitive platinum-based chemoradiotherapy and has become the current standard of care for patients with stage III locally advanced NSCLC. Immune checkpoint blockade is associated with increased risk of immunotherapy-related adverse events, which can be managed most effectively when detected early, ideally in the context of a multidisciplinary approach. Pneumonitis represents the potentially most severe and life-threatening of all reported immunotherapy-related adverse events, but it is further complicated in the context of recent prior therapies also known to cause pulmonary toxicity, such as radiotherapy. However, there are major gaps in our ability to identify immunotherapy-related pneumonitis and distinguish it from radiation pneumonitis. This review aims to define the key steps in the detection, diagnosis, and treatment of immunotherapy-related pneumonitis.
AB - Approximately one third of patients with non–small-cell lung cancer (NSCLC) present with stage III or locally advanced NSCLC. These patients have historically been managed with chemoradiotherapy. However, outcomes for these patients remain poor, with a 5-year survival rate between 15% and 32%. Immune checkpoint inhibitors have revolutionized the treatment of patients with NSCLC. One such agent, durvalumab, a selective high-affinity human immunoglobulin G1 monoclonal antibody that blocks programmed cell death ligand 1 binding to programmed cell death protein 1 and cluster of differentiation 80, was recently approved in the consolidation setting after completion of definitive platinum-based chemoradiotherapy and has become the current standard of care for patients with stage III locally advanced NSCLC. Immune checkpoint blockade is associated with increased risk of immunotherapy-related adverse events, which can be managed most effectively when detected early, ideally in the context of a multidisciplinary approach. Pneumonitis represents the potentially most severe and life-threatening of all reported immunotherapy-related adverse events, but it is further complicated in the context of recent prior therapies also known to cause pulmonary toxicity, such as radiotherapy. However, there are major gaps in our ability to identify immunotherapy-related pneumonitis and distinguish it from radiation pneumonitis. This review aims to define the key steps in the detection, diagnosis, and treatment of immunotherapy-related pneumonitis.
KW - Chemotherapy
KW - Immune-related adverse events
KW - Locally advanced non–small-cell lung cancer
KW - Pulmonary toxicities
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85086870395&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086870395&partnerID=8YFLogxK
U2 - 10.1016/j.cllc.2020.02.025
DO - 10.1016/j.cllc.2020.02.025
M3 - Review article
C2 - 32576443
AN - SCOPUS:85086870395
SN - 1525-7304
VL - 21
SP - e435-e444
JO - Clinical lung cancer
JF - Clinical lung cancer
IS - 5
ER -